/

Empresas

As

No verificado

AstraZeneca

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

125 Comunicados de prensa

Ver todos los comunicados de prensa

14/09/2026

Ciencia

Medicina - Varios

Sanidad

Biotecnología

Farmacéutica

Salud

Oncología

Industria

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

Fuente

Editor

1.00

0

14/09/2026

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Eventos

Industria

TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

Fuente

Editor

1.00

0

08/09/2026

Industria

Ciencia

Medicina - Varios

Sanidad

Biotecnología

Farmacéutica

Salud

Oncología

IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer

Fuente

Editor

1.00

0

08/09/2026

Eventos

Industria

Biotecnología

Sanidad

Salud

Farmacéutica

Medicina - Varios

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials

Fuente

Editor

1.00

0

04/09/2026

Industria

Ciencia

Higiene alimentaria

Medicina - Varios

Biotecnología

Farmacéutica

Ir de compras

Salud

Oncología

ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer

Fuente

Editor

1.00

0

01/09/2026

Industria

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer

Fuente

Editor

1.00

0

27/08/2026

Industria

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints

Fuente

Editor

1.00

0

17/08/2026

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

Fuente

Editor

1.00

0

17/08/2026

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

Fuente

Editor

1.00

0

27/07/2026

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0